FindTrial
Sign In

Relationship between serum FGF-23 and OC in patients with type 2 diabetes mellitus complicated with lower extremity arterial disease

Relationship between serum FGF-23 and OC in patients with type 2 diabetes mellitus complicated with lower extremity arterial disease

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900022368
Enrollment
Unknown
Registered
2019-04-08
Start date
2019-04-04
Completion date
Unknown
Last updated
2019-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes

Interventions

Diabetes without lower extremity arterial disease group:No
Combined lower extremity arterial disease group:No
Lower extremity arterial occlusion:No

Sponsors

The First Affiliated Hospital of Harbin Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 178 patients with type 2 diabetes mellitus (113 males, 65 females, age range: 19-85 years) enrolled in the Department of Endocrinology and Metabolism, the First Affiliated Hospital of Harbin Medical University, who met the inclusion criteria.

Exclusion criteria

Exclusion criteria: Patients with long-term use of hormones and other drugs that affect bone metabolism are excluded. In addition, individuals with liver dysfunction (acute major hepatitis; alanine amino acid) non-transferase, or aspartate aminotransferase > 1.5 times the upper limit of normal), renal insufficiency (serum creatinine = 115 µmol / L, Or glomerular filtration rate [GFR] <60 mL / min / 1.73 m 2), hypothyroidism or hypothyroidism, acute infection, malignancy or mental illness were also excluded.

Design outcomes

Primary

MeasureTime frame
FGF-23;OC;—

Countries

China

Contacts

Public ContactLiu Haoling
liuhaoling@126.com+86 13633627146

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026